Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

默克（Merck）周二宣布，其重磅免疫疗法Keytruda与辉瑞（Pfizer）的抗体药物偶联物Padcev联合疗法，在治疗一种膀胱癌方面显示出积极成果。

辉瑞（Pfizer）周二宣布，其抗体药物偶联物Padcev与默克（Merck）的免疫疗法Keytruda联合使用，在治疗一种膀胱癌方面显示出积极效果。 这家美国生物制药公司表示，一项III期试验表明，在接受治疗的患者中，无事件生存期（研究的主要终点）出现了“具有临床相关性和统计学意义的改善”。两项次要终点也取得进展，包括总生存期的改善，以及与单独手术相比，对于不适合化疗的浸润性膀胱癌（MIBC）患 ...

The combination of Padcev, a bladder cancer drug from Pfizer Inc. and Astellas Pharma Inc., and Merck & Co.’s blockbuster immunotherapy Keytruda extended the lives of patients with a hard-to-treat ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Pfizer’s Padcev plus Keytruda combo shows significant survival gains in muscle‑invasive bladder cancer and could become ...

Pfizer (NYSE:PFE) and Astellas Pharma (OTCPK:ALPMF) announced on Tuesday that their jointly developed antibody-drug conjugate ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Pfizer said its antibody-drug conjugate Padcev extended survival when combined with the immunotherapy Keytruda in some ...

The EV-303 study is evaluating PADCEV ™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA ™ (pembrolizumab), a PD-1 inhibitor, as neoadjuvant and adjuvant ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...